Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Gain Therapeutics Inc (GANX)

Gain Therapeutics Inc (GANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,795
  • Shares Outstanding, K 16,220
  • Annual Sales, $ 60 K
  • Annual Income, $ -22,270 K
  • 60-Month Beta 0.43
  • Price/Sales 940.76
  • Price/Cash Flow N/A
  • Price/Book 3.48
Trade GANX with:

Options Overview Details

View History
  • Implied Volatility 192.38% ( -10.07%)
  • Historical Volatility 62.13%
  • IV Percentile 90%
  • IV Rank 46.74%
  • IV High 393.48% on 04/05/24
  • IV Low 15.90% on 11/09/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 2,122
  • Open Int (30-Day) 1,973

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.31
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +30.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.92 +3.59%
on 04/16/24
4.04 -25.00%
on 04/04/24
-0.77 (-20.26%)
since 03/26/24
3-Month
2.92 +3.59%
on 04/16/24
5.33 -43.15%
on 02/07/24
-0.72 (-19.20%)
since 01/26/24
52-Week
2.00 +51.50%
on 11/22/23
5.65 -46.37%
on 05/05/23
-2.11 (-41.05%)
since 04/26/23

Most Recent Stories

More News
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates

Scynexis (SCYX) delivered earnings and revenue surprises of 10.71% and 24.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SCYX : 1.5400 (+4.76%)
GANX : 3.06 (-0.33%)
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of -13.33% and 2.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CPRX : 14.99 (+2.11%)
GANX : 3.06 (-0.33%)
Analysts Estimate Gain Therapeutics, Inc. (GANX) to Report a Decline in Earnings: What to Look Out for

Gain Therapeutics, Inc. (GANX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GANX : 3.06 (-0.33%)
JAZZ : 109.58 (+2.00%)
Champions Oncology, Inc. (CSBR) Reports Q3 Loss, Tops Revenue Estimates

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -200% and 2.26%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?...

CSBR : 5.00 (-1.19%)
GANX : 3.06 (-0.33%)
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

GANX : 3.06 (-0.33%)
CASI : 2.45 (+6.30%)
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 10.17% and 42.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

IPSC : 2.96 (-6.03%)
GANX : 3.06 (-0.33%)
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 4.76% and 12.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

LYRA : 4.83 (-6.58%)
GANX : 3.06 (-0.33%)
Theravance Biopharma (TBPH) Reports Q3 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 4.55% and 34.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TBPH : 9.17 (+0.33%)
GANX : 3.06 (-0.33%)
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates

Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 3.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AMRX : 5.89 (-0.17%)
GANX : 3.06 (-0.33%)
Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

GANX : 3.06 (-0.33%)
VVOS : 2.55 (+3.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized...

See More

Key Turning Points

3rd Resistance Point 3.45
2nd Resistance Point 3.32
1st Resistance Point 3.20
Last Price 3.06
1st Support Level 2.95
2nd Support Level 2.82
3rd Support Level 2.70

See More

52-Week High 5.65
Fibonacci 61.8% 4.26
Fibonacci 50% 3.83
Fibonacci 38.2% 3.39
Last Price 3.06
52-Week Low 2.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar